Belkyra Brand ad

BELKYRA® (Also Known as KYBELLA®) Now at RCA!

March 1, 2017

Until now, patients with submental fullness more commonly described as a ‘double chin’ have had few options when it comes to reducing chin fat.

Often diet and exercise don’t always help this area, as ageing, genetics and weight fluctuations all influence submental fullness.

Thankfully BELKYRA® (also known as KYBELLA®) is now available in Australia and available at Rejuvenation Clinics of Australia. Dr Garry Cussell was one of few doctors selected to attend theBelkyra injection Australian launch!

What is the BELKYRA® injection and how does it work?

BELKYRA® is a prescription medicine and is the only FDA-approved, non-invasive injectable treatment to reduce the fat below the chin improving the appearance of moderate to severe ‘submental fat’.

The active ingredient in BELKYRA® is a naturally occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected into the fat beneath the chin, BELKYRA® kills the fat cells, once the fat cells are destroyed, these cells can no longer store or accumulate fat. The result is a visible reduction of fat under the chin,  a more defined jawline and contoured neck area.

Does BELKYRA double chin reduction really work?

BELKYRA®  is a clinically proven treatment which can be customised to suit each patients’ anatomy and circumstances. More than 75% of BELKYRA® patients reported satisfaction with the belkyra femaleappearance of their face and chin. Visible results can be seen in 2-4 treatments and re-treatment is not expected, as results are maintained for at least 4 years.

How many treatments will I need?

Each treatment performed at Rejuvenation Clinics of Australia includes a tailored treatment plan based on your chin profile. At each treatment, you will be given multiple tiny injections under your chin. You may receive up to 6 treatment sessions, spaced at least 1 month apart however many patients experience visible results in 2 to 4 treatments. Only 59% of patients received 6 treatments in clinical studies.

What are the possible side effects?

As with other injectable treatments, the most common side effects are swelling, bruising, pain, numbness, redness and areas of hardness around the treatment area. In more exceptional cases BELKYRA® can result in temporary trouble swallowing and temporary nerve injury in the jaw that affects the smile and causes short-term facial muscle weakness.

How long will results last?

When injected into fat under the chin, BELKYRA® causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat. After reaching your desired aesthetic, further treatment is not expected.

Who is suitable for BELKYRA®

Patients 18 years of age or above who have ‘submental fullness’ and do not have too much excess skin in the neck are suitable for the treatment. BELKYRA® can be used in conjunction with Skin Tightening with Ultrasound to tighten and strengthen the skin once BELKYRA® has been performed. It is mandatory to have a proper consultation by a trained health provider prior to treatment to get accurate advice, and to determine if the patient is the right candidate for the treatment.

Who is unsuitable for BELKYRA®?

Before receiving the treatment all medical conditions should be discussed with the medical provider, including if you:

  1. Had/plan to have surgery on your face, neck, or chin.
  2. Had cosmetic treatments on your face, neck, or chin.
  3. Had or have medical conditions or infections around the neck area
  4. Have had or have trouble swallowing or bleeding problems
  5. Are pregnant or plan to become pregnant, breastfeeding or plan to breastfeed.

The healthcare provider should know about all the medicines consumed, including prescription and over-the-counter medicines, vitamins and herbal supplements.

 

*All informaion has been sourced from: Your Guide to BELKYRA by Allergan, 2017

For More information, or to book a consultation, call 1300 88 99 35

Leave a public comment:

Your email address will not be published. Required fields are marked *

Back to listing